Elsevier

Clinical Therapeutics

Volume 26, Issue 12, December 2004, Pages 1960-1975
Clinical Therapeutics

Anakinra: Review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis

https://doi.org/10.1016/j.clinthera.2004.12.019Get rights and content

Abstract

Background:

Interleukin-1 (IL-1) plays an important role in the pathophysiology and progression of rheumatoid arthritis (RA) by contributing to destruction of cartilage, bone, and periarticular tissues. Inhibiting IL-1 synthesis or activity with the use of recombinant human IL-1 receptor antagonist (anakinra) may prove to be an effective approach to the treatment of RA.

Objective:

The purpose of this article is to review the effects of anakinra in the treatment of RA.

Methods:

A MEDLINE search from 1982 to 2003 was used to identify animal studies and randomized clinical trials of anakinra and other therapies that target IL-1.

Results:

Clinical trials of anakinra have shown that it reduces the signs and symptoms of active disease and slows the rate of radiographic destruction in adults with RA. With anakinra 150 mg/d, 43% of patients achieved an American College of Rheumatology (ACR) 20% response, compared with 27% with placebo (P = 0.014). The ACR20 score indicates at least 20% improvement in the ACR composite score, which includes assessment of tender and swollen joint count, and other clinical end points such as pain and disability assessment. Patients treated with anakinra also experienced a 59% reduction in new bony erosion compared with controls (P < 0.001) and a 65% reduction in joint space narrowing as measured by the modified Sharp score (P = 0.020). Injection-site reactions were the most commonly reported adverse event, occurring in 50%, 73%, and 81% of patients receiving anakinra 30, 75, and 150 mg/d, respectively, compared with 25% of patients receiving placebo. Few serious adverse events were reported, and they typically occurred in patients receiving the highest daily dosage.

Conclusions:

IL-1 is an important cytokine in promoting the damage associated with RA. Anakinra is mildly to moderately effective and well tolerated in patients with active RA when used as monotherapy or in combination with methotrexate.

References (81)

  • ArendWP

    Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist

    Semin Arthritis Rheum

    (2001)
  • SeckingerP et al.

    An interleukin 1 inhibitor affects both cell-associated interleukin 1-induced T cell proliferation and PGE2/collagenase production by human dermal fibroblasts and synovial cells

    Immunobiology

    (1990)
  • HendersonB et al.

    Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist

    Cytokine

    (1991)
  • GranowitzEV et al.

    Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans

    Cytokine

    (1992)
  • BresnihanB

    The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis

    Semin Arthritis Rheum

    (2001)
  • BresnihanB

    Pathogenesis of joint damage in rheumatoid arthritis

    J Rheumatol

    (1999)
  • GoldringSR et al.

    Mechanisms of bone loss in inflammatory arthritis: Diagnosis and therapeutic implications

    Arthritis Res

    (2000)
  • ScottDL et al.

    The links between joint damage and disability in rheumatoid arthritis

    Rheumatology (Oxford)

    (2000)
  • WollheimFA

    Predictors of joint damage in rheumatoid arthritis

    APMIS

    (1996)
  • GuedesC et al.

    Mortality in rheumatoid arthritis

    Rev Rhum Engl Ed

    (1999)
  • PincusT

    The underestimated long term medical and economic consequences of rheumatoid arthritis

    Drugs

    (1995)
  • PincusT et al.

    Premature mortality in patients with rheumatoid arthritis: Evolving concepts

    Arthritis Rheum

    (2001)
  • van der HeijdeDM

    Joint erosions and patients with early rheumatoid arthritis

    Br J Rheumatol

    (1995)
  • van der HeijdeDM et al.

    Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis

    Arthritis Rheum

    (1992)
  • JiangY et al.

    A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores

    Arthritis Rheum

    (2000)
  • GraudalNA et al.

    Radiographic progression in rheumatoid arthritis: A long-term prospective study of 109 patients

    Arthritis Rheum

    (1998)
  • CunnaneG et al.

    Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis

    Rheumatology (Oxford)

    (1999)
  • WeinblattME

    Rheumatoid arthritis: Treat now, not later!

    Ann Intern Med

    (1996)
  • HochbergMC

    Early aggressive DMARD therapy: The key to slowing disease progression in rheumatoid arthritis

    Scand J Rheumatol Suppl

    (1999)
  • ChoyEH et al.

    Cytokine pathways and joint inflammation in rheumatoid arthritis

    N Engl J Med

    (2001)
  • SchiffMH

    Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis

    Ann Rheum Dis

    (2000)
  • ArendWP et al.

    Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis

    Arthritis Rheum

    (1995)
  • KoopmanWJ

    Prospects for autoimmune disease: Research advances in rheumatoid arthritis

    JAMA

    (2001)
  • FontanaA et al.

    Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis

    Rheumatol Int

    (1982)
  • WoodDD et al.

    Isolation of an interleukin-1-like factor from human joint effusions

    Arthritis Rheum

    (1983)
  • NouriAM et al.

    Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids

    Clin Exp Immunol

    (1984)
  • DinarelloCA et al.

    The role of interleukin-1 in disease

    N Engl J Med

    (1993)
  • GabayC et al.

    Treatment of rheumatoid arthritis with IL-1 inhibitors

    Springer Semin Immunopathol

    (1998)
  • MiossecP et al.

    Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid

    Arthritis Rheum

    (1986)
  • BendtzenK et al.

    Interleukin-1-like activities in synovial fluids of patients with rheumatoid arthritis and traumatic synovitis

    Rheumatol Int

    (1985)
  • Cited by (153)

    View all citing articles on Scopus
    View full text